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ABSTRACT 
Objective: The objective of the present work was to develop and optimize fast dissolving orodispersible films containing metoclopramide 
hydrochloride using 32 multifactorial designs. 
Methods: The films were prepared by solvent casting method using hydroxypropyl methyl cellulose E5 (HPMC E5) and sodium starch glycolate (SSG) as 
two independent variables in three levels in concentration 2.5, 3, 3.5% w/wand 1, 1.5, and 2 % respectively. The percent of in vitro drug release (Y1) and 
the disintegration time (Y2) were chosen and studied as dependent responses. The prepared films were also evaluated for their weight uniformity, 
thickness, surface pH, drug content, in vitro disintegration time, in vitro drug release, film stability and mechanical properties as folding endurance. 
Results: All the films were transparent. The films weight (mg) was ranging from 63±0.78 to 86±0.82 while the film thickness (mm) and the folding 
endurance range from 0.22±0.53, 50±0.58 to 0.32±0.35 and 90±0.84 respectively. The drug content (mg %) was studied, and it ranges from 
98.24±1.08 to 99.07±1.02. It was found that the relative standard deviation (% RSD) met the criteria of USP specification for drug content (>6%). In 
vitro disintegration time was tested; all films satisfied the requirement of disintegration time for fast dissolving dosage form (<1 min), it ranged 
from 2.24±1.75 to 3.18±1.87 sec. The stability studies revealed no significant differences before and after storage for the all formulations. 
Conclusion: An optimized metoclopramide HCl film was achieved that could be a benefit to a patient suffering from emesis, in which hydroxypropyl 
methylcellulose (E5) was used as a film forming polymer in its high level (3.5%) in addition to sodium starch glycolate in its high level (2%). 
Keywords: Fast dissolving orodispersible films, Optimization, Metoclopramide HCL, 32multifactorial designs 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
A fast dissolving oral film (FDF) has been successfully used to deliver 
medicines to patients having difficulty in swallowing, those with oral 
pain due to mucositis or after oral surgery, or those with nausea. 
Several film preparations have been developed for analgesics such as 
ketrolac [1] or fentanyl [2, 3], the antiemetic agent prochlorperazine 
[4] and Ca2+channel antagonist verapamil [5]. 
Fast-dissolving oral delivery systems are solid dosage forms, which 
disintegrate or dissolve within 1 min when placed in the mouth 
without drinking or chewing [6]. 
The first developed fast-dissolving dosage form consisted in tablet form, 
and the rapid disintegrating properties were obtained through a special 
process or formulation modifications [7]. More recently, fast-dissolving 
films are gaining interest as an alternative to fast-dissolving tablets to 
eliminate definitely patients’ fear of choking and overcome patent 
impediments. Fast-dissolving films are generally constituted of 
plasticized hydrocolloids or blends made of them that can be laminated 
by solvent casting or hot-melt extrusion [8]. 
Common problems are caused by foaming during the film formation 
due to the heating of the material or solvent evaporation, the flaking 
during the slitting and the cracking in the cutting phase. Furthermore, 
the films should be stable to moisture over time. Finally, to facilitate 
the handling they have to be flexible and exhibit a suitable tensile 
stress and do not stick to the packaging materials and fingers. 
Metoclopramide was chosen as a model drug, the drug selection 
based on a high frequency of prescribing, an appropriate indication 
and the age for this new dosage form. 
Metoclopramide hydrochloride is a white crystalline, odorless 
substance, and its freely soluble in water. It is used as an anti-emetic 
in the treatment of some forms of nausea and vomiting associated 
with cancer therapy, pregnancy, migraine, etc., and to increase 
gastrointestinal motility [9]. However the oral bioavailability of 
metoclopramide HCl is highly variable showing values between 32 
and 98 % due to expensive pre-systemic metabolism [10, 11]. This 
work aims to formulate, design and optimize fast dissolving 
orodispersible films of metoclopramide HCL at various 
concentration of film-forming polymer (HPMC E5) and super-
disintegrant (sodium starch glycolate) by using32 multi-factorial 
design and to evaluate their influence on the percent of in vitro drug 
release and the disintegration time. 
MATERIALS AND METHODS 
Materials 
Metoclopramide Hydrochloride, hydroxypropyl methylcellulose 
(HPMC), and sodium starch glycolate (SSG) were obtained as gift 
sample by Sedico for Pharmaceuticals (6 of October, Giza, Egypt). 
Other chemicals were purchased from ADWEC, Egypt and they were 
of analytical grade. 
Preliminary trials 
Selection of polymer 
Different grades of HPMC (k4m and E5) were tried for the 
preparation of fast dissolving orodispersible films (FDF). HPMC k4m 
did not show a good result, the film was not easily peelable, sticky in 
nature and did not give good films. 
HPMC E5 was selected for the formulation of films as it forms good 
easily peelable and non-sticky films. 
Preparation of the films 
The fast dissolving films were prepared by a solvent casting method. 
The required percentage of polymer solution (HPMC E5) (2.5, 3, and 
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3.5% w/w) was prepared by dispersing the polymer powder in 
distilled water with continuous stirring at 70 °C. After continuous 
stirring the solution was left undisturbed for five to eight hours to 
remove all the air bubbles. Accurately weighed quantity of drug, 
plasticizer and all other excipients was separately dissolved in 
distilled water in another beaker. After complete hydration of the 
polymer with water, drug-plasticizer and all other excipient 
solutions were added and mixed thoroughly, and the volume was 
made up 30 milliliters with distilled water. The polymeric 
solutions were then poured on the mold, allowed to dry at 45 °C. 
The resultant films were cut into the dimension of 2x2 cm2 in size 
in which 10 mg of metoclopramide hydrochloride was included [5, 
12]. The prepared films are packed immediately after the 
reparation in individual airtight aluminum seal packs and stored 
at 25 °C until use. 
Experimental design and statistical analysis 
A 32-factor, 3-level factorial design was used to explore response 
surfaces and constructing second-order polynomial models with 
statgraphic plus software (Version 4.1). The 3-level factorial design was 
specifically selected since it requires fewer runs than other experimental 
designs. The nonlinear computer, generated quadratic model is given as 
(equation 1): Y=β0+β1 X1+β2 X2+β12 X1X2+β11 X12+β22 X22 
Where Y is the predicted response (dependent variable); β0 is the 
model constant (arithmetic mean response); X1and X2 are the 
independent variables and represent the average result of 
changing one factor at a time from its low value to the higher one; 
The terms X1X2 represent the changes of response when the two 
factors are simultaneously changed; The terms X1X1 and X2X2 are 
used to indicate non linearity; β1 and β2 are the linear coefficients; 
β12 are the cross-product coefficient; and β11, and β22 are the 
quadratic coefficients. 3-level design, where selected each variable is 
tested at a low (-1), medium (0) and high (+1) level. The percent of 
in vitro drug release (Y1) and the disintegration time (Y2) were 
chosen and studied as dependent responses. Nine Metoclopramide 
hydrochloride FDF formulations were prepared according to 32full 
factorial designs to optimize the formulation factors and evaluate 
the main effects. The independent variables were the polymer % 
(HPMC E5) (X1) and superdisintegrant % (SSG) (X2). Three levels of 
HPMC E5 % were used 2.5, 3 and 3.5%, denoted the value-1, 0 and 
1in the above design respectively.  
Three levels of SSG concentration were chosen to be 1 %, 1.5 % and 
2 % denoted-1, 0 and 1 respectively are represented in table 1. The 
nine experimental trials and the respective observed responses are 
given in table 2. 
 
Table 1: Independent variables and the selected levels for metoclopramide oro-dispersible film formulations 
Factor Low(-1) Medium (0) High(1) 
X1 (HPMC E5 % w/w) 








Table 2: Variables and observed response in 32 factorial design of metoclopramide orodispersible film formulations 
Formulation Independent variables Dependent  variables  
 Predicted values observed values 
 X1 X2 Y1 Y2 Y1 Y2 
F1 -1 0 93.57±2.12 3.00±1.30 94.16  2.76 
F2 1 -1 94.62±3.74 2.57±2.20 94.28 2.89 
F3 0 1 92.76±1.72 3.10±3.05 92.50 3.01 
F4 1 -1 90.32±2.05 2.24±1.75 90.04 2.14 
F5 0 1 93.213.21 2.45±0.98 92.89 2.40 
F6 -1 0 90.75±1.75 2.50±0.53 94.28 2.37 
F7 1 -1 93.21±3.08 3.00±1.75 92.05 3.06 
F8 0 1 95.32±0.52 3.18±1.87 96.80 2.90 
F9 1 -1 100.00±0.56 2.52±2.00 98.82 2.73 
X1= % w/w of polymer (hydroxpropylmethyl cellulose-HPMC E5), X2=% w/w of superdisintegrant (sodium starch glycolate-SSG), Y1= % of in vitro 
drug release, Y2= disintegration time (sec) 
 
Table 3: Composition and codes of metoclopramide orodispersible film formulations 
Components    Formula code      





Citric acid (g) 
Mannitol (g) 
Aspartame (g) 









































































*HPMC E5: Hydroxypropyl methylcellulose E5, * SSG: Sodium starch glycolate 
 
Physical appearance of the film 
Appearances of the films such as transparent or opaque were 
evaluated by visual observation [8, 13]. 
Weight uniformity of the film 
The weight of film strip (2x2 cm) of metoclopramide 
hydrochloride was determined by an analytical balance 
(Shimazdu, Japan) [8]. Experiments were carried out in 
triplicates. 
Thickness of the film 
Film thickness was measured by means of a micrometer (precision± 
0.0001 mm Mitutoyo Corporation, Japan). The thickness of each film was 
measured at three different positions of the film and the average 
thickness was calculated [5]. Experiments were carried out in triplicates. 
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Folding endurance study 
It was measured manually for the prepared fast dissolving film (2 Χ 
2 cm). A strip was repeatedly folded at the same place till it broke. 
The number of times the film could be folded at the same place 
without breaking gave the value of folding endurance. This test was 
performed on three films of each formulation [14].  
Surface pH  
The surface pH of fast dissolving strip was determined in order to 
investigate the possibility of any side effects in vivo. As an acidic or 
alkaline pH may cause irritation to the oral mucosa, it was determined to 
keep the surface pH as close to neutral as possible. A combined pH 
electrode was used for this purpose. Oral strip was slightly wet with the 
help of water. The pH was measured by bringing the electrode in contact 
with the surface of the oral film (Orion Research, Inc., USA). This study 
was performed on three films of each formulation [15]. 
Drug content determination 
The content uniformity of each oral film was tested for 
metoclopramide HCl using UV spectroscopy at 273 nm. One fast-
dissolving film of 2 cm x 2 cm was selected and dissolved in 100 ml 
of phosphate buffer pH 6.8 then the concentration of the drug was 
determined from a previously constructed standard calibration 
curve. According to the USP standards, the contents of preparations 
should lay between the limits 98 to 101%. The results were 
expressed as mean of three determinations of each formulation [16]. 
In vitro disintegration studies 
Disintegration time gives an indication about the disintegration 
characteristics and dissolution characteristics of the film. The film as 
per the dimensions (2 x 2 cm) required for dose delivery was placed 
on a stainless steel wire mesh placed in a petri dish containing 10 ml 
phosphate buffer pH 6.8 at 37 °C. Time required for the film to break 
was noted as in vitro disintegration time. This test was performed on 
three films of each formulation [17, 18].  
In vitro drug release 
The in vitro dissolution test of metoclopramide HCl films was 
performed three times using (900 ml; phosphate buffer pH 6.8 
with USP paddle dissolution apparatus II (Hanson SR8-plus 80, 
USA) at 50 rpm and 37±0.5 °C temperature. The drug release was 
analyzed spectrophotometrically at λ max 273 nm using 
ultraviolet (UV) spectrophotometer by using a previously 
prepared calibration. One film was placed into each vessel and test 
sample (5 ml) was withdrawn at particular time interval (10, 20, 
30, 40, 60 and 90 Seconds) and replaced with fresh dissolution 
media maintained at 37±0.5 °C. In order to prevent the film strips 
from floating, each strip was fixed to a glass slab and placed at the 
bottom of the dissolution vessel before starting the dissolution 
test [19]. 
Accelerated stability studies 
The prepared films were packed and subjected to stability 
studies at 40 °C/75 % relative humidity (RH) for a period of 3 
mo. Samples were withdrawn at time intervals of 15 d and 
evaluated for physical parameters, pH, drug content, and drug 
release [20]. 
RESULTS AND DISCUSSION 
Characterization of fast dissolving films 
Metoclopramide orodispersible films prepared were transparent, 
colorless, thin and with no spots on the film surface. The prepared 
film was evaluated for the following parameters: Physical 
Appearance of the film, weight uniformity of the film, the thickness 
of the film, folding endurance study, surface pH, drug content 
determination and in vitro disintegration studies as shown below 
in table 4. 
All the films were transparent. The films weight (mg) was ranging 
from 63± 0.78 to 86± 0.82 while the film thickness (mm) and the 
folding endurance range from 0.22±0.53, 50±0.58 to 0.32±0.35 and 
90±0.84 respectively. The drug content (mg %) was studied and it 
range from 98.24± 1.08 to 99.07±1.02. It was found that the relative 
standard deviation (% RSD) met the criteria of USP specification for 
drug content (>6%) [21]. 
In vitro disintegration time was tested; all films satisfied the 
requirement of disintegration time for fast dissolving dosage form 
(<1 min), it ranged from 2.24±1.75-3.18±1.87 sec. 
 










pHa Drug content 
(mg %)a 
In vitro disintegration 
(sec)a 
F1 Transparent 66.00±0.23 0.24±0.5 50±0.58 6.80±0.2 98.81±1.17 3.00±1.30 
F2 Transparent 76.00±0.56 0.23±0.14 58±0.47 6.90±2.4 98.24±1.08 2.57±2.20 
F3 Transparent 63.00±0.78 0.31±0.81 60±0.59 7.05±1.4 99.05±1.51 3.10±3.05 
F4 Transparent 76.00±1.25 0.32±0.35 60±1.44 7.08±0.8 99.47±0.68 2.24±1.75 
F5 Transparent 63.00±3.01 0.28±0.42 64±1.12 6.94±1.7 98.84±0.73 2.45±0.98 
F6 Transparent 76.00±2.73 0.24±0.14 67±0.64 6.85±1.1 98.39±0.71 2.50±0.53 
F7 Transparent 70.00±2.10 0.22±0.53 80±1.04 6.91±1.0 98.47±1.31 3.00±1.75 
F8 Transparent 86.00±0.82 0.30±0.81 82±1.01 6.87±0.8 98.64±1.24 3.18±1.87 
F9 Transparent 75.00±0.75 0.27±0.24 90±0.84 7.08±0.5 99.07±1.02 2.52±2.00 
amean±SD, n=3. 
 
In vitro drug release 
The in vitro drug release of different films was investigated and the 
results are represented in fig. 1. The release of metoclopramide from 
its film can be ranked in the following descending order: 
F9>F4>F8>F2>F5=F7>F1>F3>F6 where the amount of drug release 
after 30 min was found to be 100%, 97.3%, 95.32%, 94.62 %, 
93.21%, 93.57%, 92.76% and 90.75%, respectively.  
Formulations F9 was observed to have the highest release, this was 
due to the presence of the highest concentration of water soluble 
hydrophilic polymers (HPMC E5 3.5%) which dissolves rapidly and 
introduce porosity. The void volume is thus expected to be occupied 
by the external solvent which diffuses into the film and thereby 
accelerate dissolution. Also the presence of SSG (2%) which act as 
super disintegrant increase the rate of film disintegration. The 
results of metoclopramide films are in agreement with Raju et al., 
[22], who showed that the presence of highest concentration of 
water soluble hydrophilic polymers (HPMC E5) increases the release 
from the prepared films. Also the increase in the amount of 
hydrophilic carrier leads to the increase in the wettability and 
dispersibility of the drug from the film resulting in the dissolution of 
the film. [23] This result is matched with that observed in the 
enhancement of dissolution of fenofibrate. [24] 
Optimization of formulation using 32 multifactorial designs 
Nine metoclopramide hydrochloride FDF formulations were 
prepared according to 32full factorial designs to optimize the 
formulation factors and evaluate the main effects. The independent 
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variables were the polymer percent (HPMC E5) (X1) and super 
disintegrant percent (SSG) (X2). Three levels of HPMC E5 percent 
were used 2.5, 3 and 3.5%, denoted the value-1, 0 and 1in the above 
design respectively. 
 
Fig. 1: In vitro drug release of fast dissolving orodispersible 
films (F1-F9) 
Three–dimensional (3D) plots and standard pareto chart for the 
percent of in vitro drug release (Y1) and the disintegration time (Y2) 
were chosen and studied as dependent responses and were drawn 
using stat graphics plus design software (version 4.1) is shown in fig. 
2-3 respectively. 
Contour plots were prepared for all the three responses Y1, Y2 andY3 
are shown in fig 8-10 c. These plots are used to study the interaction 
effects i.e. the effects of two factors at one time. The observed and 
the predicted values were shown in table 2 while the R-squared 
values were represented in table 5. 
The response Y1 which is the percent of in vitro drug release is 
represented by the following polynomial equation (equation 2): 
Y1 =113.29+13.49 X1-62.11 X2-3.79 X12+7.6X1X2+13.94 X22 
Where, Y1 is the percent of in vitro drug release, X1 is the polymer 
percent, and X2 is the superdisintegrant percent. The polynomial 
equation was generated by multiple linear regressions. The percent 
of in vitro drug releasevalues are dependent on the selected 
independent variables. The fitted equation relates the response (the 
percent of in vitro drug release) to the transformed factor as shown 
by equation 2. The results of regression analysis revealed that on 
increasing the value of X1, the percent of in vitro drug release 
increases and this is observed by the positive sign coefficient of 
β1 (the linear coefficient). While the percent of in vitro drug release 
was noticed to be decreased as the values of X2 increase, this was 
noticed by the negative sign of β2 (the linear coefficient). 
The response Y2 which is the disintegration timeis represented by 
the following polynomial equation (equation 3): 
Y2 =248.46+59.4 X1-254.8 X2-1.6 X12–34.8X1X2+119.6 X22 
The fitted equation relates the response (the disintegration 
time) to the transformed factor as shown by equation 2. The 
results of regression analysis revealed that on increasing the 
value of X1, the disintegration time increases and this is 
observed by the positive sign coefficient β1 (the linear 
coefficient). While the disintegration time was noticed to be 
decreased as the values of X2 increase, this was noticed by the 
negative sign of β1 (the linear coefficient). 
Regression analysis of the data was carried out in statistical analysis 
system (SAS) by a special cubic model. From ANOVA study on the 
data of the percent of in vitro drug release (Y1) and the 
disintegration time (Y2) is shown in table 5, the standard error was 
below 5%, indicating that the observed responses were very close to 
predicted values. The Durbin-Watson (DW) statistic tests the 
residual to determine if there is any significant correlation between 
data, since the DW value is greater than 1.4, there is probably not 
any serious autocorrelation in the residuals. 
The promising formulation was selected on the basis of the accepted 
criteria of percent of in vitro drug release (Y1) anddisintegration 
time (Y2). From the obtained results, hydroxypropyl methyl cellulose 
(E5) as a film forming polymer was used inits high level (3.5%) in 
addition to sodium starch glycolate in its high level (2%). These 
criteria were found in formulation F9 as the observed values were 







Fig. 2: (2. a) Response surface plot, (2. b) Standard pareto chart 
and, (2. c) contour plot showing the effect of X1 and X2 on the 








Fig. 3: (3. a) Response surface plot, fig. (3. b) standard pareto chart 
and fig. (3. c) contour plot showing the effect of X1 and X2 on 
disintegration time (Y2) 
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Table 5: Summary of results of regression analysis for responses Y1 (percent of in vitro drug release) and Y2 (disintegration time) 
Response R2 Adjusted R2 Standard error Mean absolute error Durbin-Watson statistic 
In vitro drug release  88.137 68.366 1.598 0.780 2.040 
(Y1) Disintegration time (Y2) 62.983 1.289 20.284 10.359 2.415 
 
Table 6: Observed and predicted values of the responses for the optimized metoclopramide Fast dissolving orodispersible Film (F9) 
Response Observed value Predicted value Residual 
In vitro drug release (Y1)  100 98.82 -1.18 
Disintegration time (Y2) 151.2 163.96 12.76 
 
Stability study 
After subjecting all formulations to stability studies at 40 °C/75 % 
relative humidity (RH) for a period of 3 mo, samples were 
withdrawn at time intervals of 15 d and evaluated for physical 
parameters, pH, drug content, and drug release. The stability studies 
revealed no significant differences before and after storage for the 
all formulations. 
CONCLUSION 
The main aims and objective of the present study was to formulate, 
design and optimize fast dissolving oro-dispersible films of 
metoclopramide HCL at various concentration of film forming 
polymer (HPMC E5) and superdisintegrant (sodium starch 
glycolate) by using 32 multi factorial design and to evaluate their 
influence on the percent of in vitro drug release and the 
disintegration time. The films were prepared using solvent casting 
method using HPMC as polymer and SSG as a super disintegrant. 
HPMC was selected as the polymer used for their matrix forming 
properties while sodium starch glycolate (SSG) is used for its super 
disintegrant effect. The study shows that the use of 32factorial 
designs are valid in predicting the optimized formulation which was 
found in formulation F9 as the observed values were very close to 
the predicted ones, and in which hydroxypropyl methyl cellulose 
(E5) was used as a film forming polymer in its high level (3.5%) in 
addition to sodium starch glycolate in its high level (2%). The 
stability studies revealed no significant differences before and after 
storage for the selected formula. 
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